Mayne Pharma Group (AU:MYX) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Mayne Pharma Group has announced a significant change in the securities interest of its director, Shawn Patrick O’Brien. As of December 2, 2024, O’Brien acquired an additional 301,455 Performance Rights and 35,170 RSU Performance Rights, increasing his direct holdings. This change reflects O’Brien’s growing stake in the company, potentially signaling confidence in Mayne Pharma’s future performance.
For further insights into AU:MYX stock, check out TipRanks’ Stock Analysis page.
